Javascript must be enabled to continue!
Drug Metabolizing Enzyme and Transporter Genes Associated with Plasma Risperidone Level in Thai Autism Spectrum Disorder
View through CrossRef
BackgroundThe associations between genetic variants of drug metabolizing enzyme and transporter (DMET) genes and steady-state plasma concentrations of risperidone, 9-hydroxyrisperidone, total active-moiety, and metabolic ratio remain unclear.ObjectiveThe objective of the present study was to present the results of the association between genetic variants of DMET gene and steady-state plasma concentration risperidone and its metabolite using Affymetrix DMET Plus genotyping microarray.MethodsSubjects eligible for this study included male and female adolescents with ASD diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria and being treated with risperidone for at least 4 weeks prior to the blood sample collection. Blood samples were drawn prior to the next dose of risperidone intake to determine the steady-state plasma trough concentrations of risperidone and 9-hydroxyrisperidone. Genotyping profile was obtained using the microarray. Steady-state plasma risperidone and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay.ResultsThe polymorphisms of UGT2B4, CYP2D6 were highly associated with metabolic ratio. Of all the DMET analysis, ABCB11 (3084A > G, 420A > G, 368G > A, and 236G > A) and ADH7 (690G > A and –5360G > A) were found to be associated with plasma concentrations of risperidone (P < 0.01). In addition, 6 genetic variations among the SLC transporter family were associated with the plasma concentration of 9-hydroxyrisperidone.DiscussionsThis study provides a pharmacogenomic approach to investigate further among the DMET genetic variants which influence plasma concentration of risperidone. The treatment of ASD should be based on genetic factors making the challenge of psychopharmacological treatment more efficacious with lesser adverse events.Disclosure of interestThe author has not supplied his/her declaration of competing interest.
Title: Drug Metabolizing Enzyme and Transporter Genes Associated with Plasma Risperidone Level in Thai Autism Spectrum Disorder
Description:
BackgroundThe associations between genetic variants of drug metabolizing enzyme and transporter (DMET) genes and steady-state plasma concentrations of risperidone, 9-hydroxyrisperidone, total active-moiety, and metabolic ratio remain unclear.
ObjectiveThe objective of the present study was to present the results of the association between genetic variants of DMET gene and steady-state plasma concentration risperidone and its metabolite using Affymetrix DMET Plus genotyping microarray.
MethodsSubjects eligible for this study included male and female adolescents with ASD diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria and being treated with risperidone for at least 4 weeks prior to the blood sample collection.
Blood samples were drawn prior to the next dose of risperidone intake to determine the steady-state plasma trough concentrations of risperidone and 9-hydroxyrisperidone.
Genotyping profile was obtained using the microarray.
Steady-state plasma risperidone and 9-hydroxyrisperidone were measured using liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay.
ResultsThe polymorphisms of UGT2B4, CYP2D6 were highly associated with metabolic ratio.
Of all the DMET analysis, ABCB11 (3084A > G, 420A > G, 368G > A, and 236G > A) and ADH7 (690G > A and –5360G > A) were found to be associated with plasma concentrations of risperidone (P < 0.
01).
In addition, 6 genetic variations among the SLC transporter family were associated with the plasma concentration of 9-hydroxyrisperidone.
DiscussionsThis study provides a pharmacogenomic approach to investigate further among the DMET genetic variants which influence plasma concentration of risperidone.
The treatment of ASD should be based on genetic factors making the challenge of psychopharmacological treatment more efficacious with lesser adverse events.
Disclosure of interestThe author has not supplied his/her declaration of competing interest.
Related Results
Disparities in autism spectrum disorder diagnoses among 8-year-old children in Colorado: Who are we missing?
Disparities in autism spectrum disorder diagnoses among 8-year-old children in Colorado: Who are we missing?
There is often a large time gap between caregivers’ initial concerns and the diagnosis of autism spectrum disorder. The current study aimed to identify factors associated with miss...
9‐Hydroxyrisperidone‐Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder
9‐Hydroxyrisperidone‐Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder
AbstractAlthough our previous study revealed an association between prolactin level and risperidone dosage, data regarding the plasma concentration of risperidone are lacking. Ther...
Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone
Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone
AbstractRecently, the Clinical Pharmacogenetics Implementation Consortium (CPIC) have revised recommendations for the translation of CYP2D6 genotype to phenotype. Changes affect ph...
Tele-assessment of young children referred for autism spectrum disorder evaluation during COVID-19: Associations among clinical characteristics and diagnostic outcome
Tele-assessment of young children referred for autism spectrum disorder evaluation during COVID-19: Associations among clinical characteristics and diagnostic outcome
Since the onset of the COVID-19 pandemic, there has been a rapid acceleration of innovative research on health services delivery, including real-world clinical implementation and e...
Magnetohydrodynamics enhanced radio blackout mitigation system for spacecraft during planetary entries
Magnetohydrodynamics enhanced radio blackout mitigation system for spacecraft during planetary entries
(English) Spacecraft entering planetary atmospheres are enveloped by a plasma layer with high levels of ionization, caused by the extreme temperatures in the shock layer. The charg...
Use of Risperidone as Augmentation Treatment for Major Depressive Disorder
Use of Risperidone as Augmentation Treatment for Major Depressive Disorder
Objective To review the efficacy and safety of risperidone for augmentation treatment In patients with major depressive disorder who fail to achieve adequate response to antidepres...
TỶ LỆ MỔ LẤY THAI VÀ CÁC YẾU TỐ LIÊN QUAN Ở SẢN PHỤ MANG THAI CON SO TẠI BỆNH VIỆN ĐA KHOA TỈNH GIA LAI NĂM 2023
TỶ LỆ MỔ LẤY THAI VÀ CÁC YẾU TỐ LIÊN QUAN Ở SẢN PHỤ MANG THAI CON SO TẠI BỆNH VIỆN ĐA KHOA TỈNH GIA LAI NĂM 2023
Mục tiêu: Xác định tỷ lệ mổ lấy thai của sản phụ có con so tại Bệnh viện Đa khoa tỉnh Gia Lai và tìm hiểu một số yếu tố liên quan đến nguyên nhân mổ lấy thai con so. Phương pháp ng...
Pharmacogenomics Factors Influencing the Effect of Risperidone on Prolactin Levels in Thai Pediatric Patients With Autism Spectrum Disorder
Pharmacogenomics Factors Influencing the Effect of Risperidone on Prolactin Levels in Thai Pediatric Patients With Autism Spectrum Disorder
We investigated the association between genetic variations in pharmacodynamic genes and risperidone-induced increased prolactin levels in children and adolescents with autism spect...

